Prognostic significance of the standardized uptake value of pre-therapeutic 18F-FDG PET in patients with malignant lymphoma Authors
First Online: 04 June 2010 Received: 19 February 2010 Accepted: 19 May 2010 DOI:
10.1007/s12032-010-9584-2 Cite this article as: Ahmadzadehfar, H., Rodrigues, M., Zakavi, R. et al. Med Oncol (2011) 28: 1570. doi:10.1007/s12032-010-9584-2 Abstract
Metabolic imaging with F-18-fluorodeoxyglucose (
18F-FDG) positron-emission tomography (PET) is widely used for staging and treatment evaluation of malignant lymphoma. To date, only a few studies have indicated that lower glucose metabolism measured by 18F-FDG PET before or early in the course of treatment of malignant lymphoma is associated with a favorable outcome. The aim of this study was to assess the prognostic capability of the 18F-FDG PET maximum standardized uptake value (SUV max), a semiquantitative measurement of glucose metabolism, at the time of diagnosis of malignant lymphoma. We retrospectively analyzed data from 69 patients (median age: 61 and range 23–80) with malignant lymphoma (22 patients with Hodgkin’s disease [HD] and 47 patients with Non-Hodgkin’s lymphoma [NHL]) who had not received treatment before 18F-FDG PET imaging. Metabolic remission according to PET results was observed after chemotherapy in 50 patients (72.5%), while progressive disease or relapse was diagnosed in 19 patients (27.5%). Clinical follow-up revealed relapse in 4/50 patients with prior metabolic remission. A significantly lower ( P < 0.01) baseline SUV max level (median: 4.6 and range 1.5–12.9) was found in patients with subsequent metabolic and clinical response than in those with progressive or relapsing disease (median SUV max 10.4, range 2.0–17.9). Thirty-seven of thirty-nine patients with baseline SUV max < 7.4 achieved long-lasting remission after completion of chemotherapy (median follow-up: 28 months, range 4–112 months). Within this group with favorable outcome, there were no significant differences between SUV max values in HD and NHL. A heterogeneous outcome was noted in 25 patients with a SUV max ≥ 7.4 and ≤ 12.9 at diagnosis, with 16 patients experiencing disease progression or relapse and nine patients extended remission. The five patients with SUV max > 12.9 showed disease progression at follow-up. Semiquantitative measurement of glucose metabolism (SUV max) by 18F-FDG PET at diagnosis is a predictor of outcome of patients with malignant lymphoma. Keywords FDG PET SUV Lymphoma Prognostic References
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–14.
Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.
The International non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.
Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47.
Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci. 2008;105:13520–5.
Baggetto LG. Deviant energetic metabolism of glycolytic cancer cells. Biochemie. 1992;74:959–74.
Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492–5.
Isselbacher KJ. Sugar and amino acid transport by cells in culture: differences between normal and malignant cells. N Engl J Med. 1972;286:929–33.
Warburg O. The metabolism of tumors. New York: Richard R Smith, Inc.; 1931.
Erasmus JJ, McAdams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am J Roentgenol. 1998;170:1369–73.
Rivenzon-Segal D, Rushkin E, Polak-Charcon S, Degani H. Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol Endocrinol Metab. 2000;279:E508–19.
Schlüter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71–6.
Younes M, Brown RW, Mody DR, et al. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995;15:2895–8.
Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39:1016–20.
Gallagher BM, Fowler JS, Gutterson NE. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18 F] 2-deoxy-2-fluoro-
-glucose. J Nucl Med. 1978;19:1154–61.
Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1–93.
Huang SC. Anatomy of SUV. Nucl Med Biol. 2000;27:643–6.
Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery. 2001;130:941–6.
Dimitrakopoulou-Stauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med. 2003;47:8–13.
Lapela M, Grenman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-
-glucose. Radiology. 1995;197:205–11.
Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 1995;86:3522–7.
Schöder H, Noy A, Gönen M, et al. Intensity of 18-fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;21:4643–51.
Rodriguez M, Rehn S, Ahlstrom H, et al. Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med. 1995;36:1790–6.
Wong RJ, Lin DT, Schöder H, et al. Diagnostic and prognostic value of [
F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199–208.
Eary JF, O’Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002;29:1149–54.
Fukunaga T, Okazumi S, Koide Y, et al. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med. 1998;39:1002–7.
Nakata B, Chung YS, Nishimura S, et al. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer. 1997;79:695–9.
Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18) F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol. 1999;17:3201–6.
Woodard H, Bigler R, Freed B, et al. Expression of tissue isotope distribution. J Nucl Med. 1975;16:958–9.
Cremerius U, Fabry U, Neuerburg J, et al. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma. Nucl Med. 2001;40:23–30.
Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. RadioGraphics. 2003;23:315–40.
Schaefer NG, Taveran C, Strobel K, et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy—is biopsy of FDG-avid lesions still needed? Radiology. 2007;244:257–62.
Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Eur J Nucl Med Mol Imaging. 2003;30:682–8.
Suh C, Kang YK, Roh JL, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphoma of the head and neck. J Nucl Med. 2008;49:1783–9.
Ong L, Song I, Yu S, et al. 2-[18F]-2-deoxy-
-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Acta Radiol. 2008;49:1145–53.
Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.
Lin C, Itti E, Haioun C, et al. Early prediction of 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma; SUV-based assessment versus visal analysis. J Nucl Med. 2007;48:1626–32.
Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–33.
PubMed CrossRef Copyright information
© Springer Science+Business Media, LLC 2010